Novel approaches for the treatment of infections due to multidrug-resistant bacterial pathogens

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Fumagalli M, Sironi M, Pozzoli U, Ferrer-Admettla A, Pattini L, Nielsen R. Signatures of environmental genetic adaptation pinpoint pathogens as the main selective pressure through human evolution. PLOS Genetics 7(11), e1002355 (2011).
  Medline CASGoogle Scholar
• 2. Vidovic N, Vidovic S. Antimicrobial resistance and food animals: influence of livestock environment on the emergence and dissemination of antimicrobial resistance. Antibiotics 9(2), 52 (2020).
  CASGoogle Scholar
• 3. Mwangi J, Hao X, Lai R, Zhang Z. Antimicrobial peptides: new hope in the war against multidrug resistance. Zool. Res. 40(6), 488–505 (2019). •• An excellent review article summarizing the efficacy of various antimicrobial peptides (AMPs) against different multidrug resistance pathogens
  MedlineGoogle Scholar
• 4. Catalão M, Pimentel M. Mycobacteriophage lysis enzymes: targeting the mycobacterial cell envelope. Viruses 10(8), 428 (2018). • Specially focused review article on mycobacteriophages with special insight into the structure and functions of lysis protein encoded by them. It also enlist various strategies employed to increase effectiveness of mycobacteriophage against clinically relevant mycobacterial pathogens.
  Google Scholar
• 5. Theuretzbacher U, Outterson K, Engel A, Karlén A. The global preclinical antibacterial pipeline. Nat. Rev. Microbiol. 18(5), 275–285 (2019).
  MedlineGoogle Scholar
• 6. Beyer P, Paulin S. The antibacterial research and development pipeline needs urgent solutions. ACS Infect. Dis. 6(6), 1289–1291 (2020).
  CASGoogle Scholar
• 7. Antibacterial products in clinical development for priority pathogens [Internet]. Who.int. (2022). www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/antibacterial-products-in-clinical-development-for-priority-pathogens
  Google Scholar
• 8. Miethke M, Pieroni M, Weber T et al. Towards the sustainable discovery and development of new antibiotics. Nat. Rev. Chem. 5(10), 726–749 (2021).
  Medline CASGoogle Scholar
• 9. [Internet]. Who.int. (2022). www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf
  Google Scholar
• 10. Murray C, Ikuta K, Sharara F et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 399, 629–55 (2022).
  Medline CASGoogle Scholar
• 11. Global Tuberculosis Report 2021 [Internet]. Who.int. (2022). www.who.int/publications/digital/global-tuberculosis-report-2021
  Google Scholar
• 12. Venkatesan P. WHO 2020 report on the antibacterial production and development pipeline. The Lancet Microbe 2(6), e239 (2021).
  MedlineGoogle Scholar
• 13. Li W, Separovic F, O'Brien-Simpson N, Wade J. Chemically modified and conjugated antimicrobial peptides against superbugs. Chem. Soc. Rev. 50(8), 4932–4973 (2021). • Summary of various medicinal chemistry approaches applied and their impact on efficacy of antimicrobial peptides against different pathogens. It includes various methods employed to potentiate activity of AMPs such as glycosylation, multimerization and lipidation etc.
  Medline CASGoogle Scholar
• 14. Peraman R, Sure S, Dusthackeer V et al. Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance. Future J. Pharmaceutic. Sci. 7(1), 56 (2021).
  MedlineGoogle Scholar
• 15. Hancock R, Alford M, Haney E. Antibiofilm activity of host defence peptides: complexity provides opportunities. Nat. Rev. Microbiol. 19(12), 786–797 (2021).
  Medline CASGoogle Scholar
• 16. Abedinzadeh M, Gaeini M, Sardari S. Natural antimicrobial peptides against Mycobacterium tuberculosis. J. Antimicrob. Chemother. 70(5), 1285–1289 (2015).
  Medline CASGoogle Scholar
• 17. van der Weide H, Vermeulen-de Jongh D, van der Meijden A et al. Antimicrobial activity of two novel antimicrobial peptides AA139 and SET-M33 against clinically and genotypically diverse Klebsiella pneumoniae isolates with differing antibiotic resistance profiles. Int. J. Antimicrob Agents 54(2), 159–166 (2019).
  MedlineGoogle Scholar
• 18. de Breij A, Riool M, Cordfunke R et al. The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms. Sci. Transl. Med. 10(423), eaan4044 (2018).
  MedlineGoogle Scholar
• 19. Wu G, Li X, Fan X et al. The activity of antimicrobial peptide S-thanatin is independent on multidrug-resistant spectrum of bacteria. Peptides 32(6), 1139–1145 (2011).
  Medline CASGoogle Scholar
• 20. Wang Y, Zhang Z, Chen L et al. Cathelicidin-BF, a snake cathelicidin-derived antimicrobial peptide, could be an excellent therapeutic agent for Acne vulgaris. PLOS ONE. 6(7), e22120 (2011).
  Medline CASGoogle Scholar
• 21. Ge Y, MacDonald D, Holroyd K, Thornsberry C, Wexler H, Zasloff M. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. 43(4), 782–788 (1999).
  Medline CASGoogle Scholar
• 22. Zhao F, Lan X-Q, Du Y et al. King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates. Zool. Res. 39(2), 87–96 (2018).
  MedlineGoogle Scholar
• 23. Fedders H, Podschun R, Leippe M. The antimicrobial peptide Ci-MAM-A24 is highly active against multidrug-resistant and anaerobic bacteria pathogenic for humans. Int. J. Antimicrob. Agents 36(3), 264–266 (2010).
  Medline CASGoogle Scholar
• 24. Qu HD, Chen B, Peng H, Wang KJ. Molecular cloning, recombinant expression, and antimicrobial activity of ec-hepcidin3, a new four-cysteine hepcidin isoform from epinepheluscoioides. Biosci. Biotechnol. Biochem. 77(1), 103–110 (2013).
  Medline CASGoogle Scholar
• 25. Falla T, Karunaratne D, Hancock R. Mode of action of the antimicrobial peptide indolicidin. J. Biol. Chem. 271(32), 19298–19303 (1996).
  Medline CASGoogle Scholar
• 26. Melo M, Castanho M. Omiganan interaction with bacterial membranes and cell wall models. Assigning a biological role to saturation. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1768(5), 1277–1290 (2007).
  Medline CASGoogle Scholar
• 27. Ohta M, Ito H, Masuda K et al. Mechanisms of antibacterial action of tachyplesins and polyphemusins, a group of antimicrobial peptides isolated from horseshoe crab hemocytes. Antimicrob. Agents Chemother. 36(7), 1460–1465 (1992).
  Medline CASGoogle Scholar
• 28. Brives C, Pourraz J. Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures. Palgrave Commun. 6(1), 100 (2020).
  Google Scholar
• 29. GradisteanuPircalabioru G, Popa L, Marutescu L et al. Bacteriocins in the era of antibiotic resistance: rising to the challenge. Pharmaceutics 13(2), 196 (2021). • Summarized review article on Nisin A: it provides comprehensive information on Nisin A and its efficacy against Gram positive pathogens including Staphylococcus, Listeria, Streptococcus, Clostridiumdifficile, Bacillus and Enterococcus.
  MedlineGoogle Scholar
• 30. Hols P, Ledesma-García L, Gabant P, Mignolet J. Mobilization of microbiota commensals and their bacteriocins for therapeutics. Trends Microbiol. 27(8), 690–702 (2019).
  Medline CASGoogle Scholar
• 31. Shin J, Gwak J, Kamarajan P, Fenno J, Rickard A, Kapila Y. Biomedical applications of nisin. J. Appl. Microbiol. 120(6), 1449–1465 (2016).
  Medline CASGoogle Scholar
• 32. Lay C, Dridi L, Bergeron M, Ouellette M, Fliss I. Nisin is an effective inhibitor of Clostridium difficile vegetative cells and spore germination. J. Med. Microbiol. 65(2), 169–175 (2016).
  MedlineGoogle Scholar
• 33. Belguesmia Y, Naghmouchi K, Chihib N-E, Drider D. Class iia bacteriocins: current knowledge and perspectives. Prokaryotic Antimicrobial Peptides. 171–195 (2011).
  Google Scholar
• 34. Garcia-Gutierrez E, Mayer M, Cotter P, Narbad A. Gut microbiota as a source of novel antimicrobials. Gut Microbes 10(1), 1–21 (2018).
  MedlineGoogle Scholar
• 35. Kumariya R, Garsa A, Rajput Y, Sood S, Akhtar N, Patel S. Bacteriocins: classification, synthesis, mechanism of action and resistance development in food spoilage causing bacteria. Microb. Pathog. 128, 171–177 (2019).
  Medline CASGoogle Scholar
• 36. Ditu L, Chifiriuc M, Pelinescu D, Avram I, Pircalabioru G, Mihaescu G. Class I and II Bacteriocins: structure, biosynthesis and drug delivery systems for the Improvement of their antimicrobial activity. Curr. Proteomics 11(2), 121–127 (2014).
  CASGoogle Scholar
• 37. Duquesne S, Destoumieux-Garzon D, Peduzzi J, Rebuffat S. Microcins, gene-encoded antibacterial peptides from enterobacteria. Nat Prod Rep. 38(45), 708–34 (2007).
  Google Scholar
• 38. Baquero F, Lanza V, Baquero M, del Campo R, Bravo-Vázquez D. Microcins in enterobacteriaceae: peptide antimicrobials in the eco-active intestinal chemosphere. Front Microbiol. 10, 2261 (2019).
  MedlineGoogle Scholar
• 39. van der Weide H, Vermeulen-de Jongh D, van der Meijden A et al. Antimicrobial activity of two novel antimicrobial peptides AA139 and SET-M33 against clinically and genotypically diverse Klebsiella pneumoniae isolates with differing antibiotic resistance profiles. Int. J. Antimicrob. Agents 54(2), 159–166 (2019).
  MedlineGoogle Scholar
• 40. Yu H, Li N, Zeng X et al. A comprehensive antimicrobial activity evaluation of the recombinant microcin J25 against the foodborne pathogens Salmonella and E. coli O157:H7 by using a matrix of conditions. Front. Microbiol. 10, 1954 (2019).
  MedlineGoogle Scholar
• 41. Chhibber S, Gondil V. Exploring potential of phage therapy for tuberculosis using model organism. Biomed. Biotechnol. Res. J. 2(1), 9 (2018).
  Google Scholar
• 42. Lin D, Koskella B, Lin H. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J. Gastrointest. Pharmacol. 8(3), 162 (2017).
  MedlineGoogle Scholar
• 43. Azimi T, Mosadegh M, Nasiri MJ, Sabour S, Karimaei S, Nasser A. Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review. Infect. Drug Resist. 12, 2943–2959 (2019).
  Medline CASGoogle Scholar
• 44. Nieth A, Verseux C, Barnert S, Süss R, Römer W. A first step toward liposome-mediated intracellular bacteriophage therapy. Expert Opin. Drug Deliv. 12(9), 1411–1424 (2015).
  MedlineGoogle Scholar
• 45. Ford M, Stenstrom C, Hendrix R, Hatfull G. Mycobacteriophage TM4: genome structure and gene expression. Tuber. Lung Dis. 79(2), 63–73 (1998).
  Medline CASGoogle Scholar
• 46. McNerney R, Traore H. Mycobacteriophage and their application to disease control. J. Appl. Microbiol. 99(2), 223–233 (2005).
  Medline CASGoogle Scholar
• 47. Mayer O, Jain P, Weisbrod T et al. Fluorescent reporter DS6A mycobacteriophages reveal unique variations in infectibility and phage production in mycobacteria. J. Bacteriol. 198(23), 3220–3232 (2016).
  Medline CASGoogle Scholar
• 48. Bajpai U, Mehta A, Eniyan K et al. Isolation and characterization of bacteriophages from India, with lytic activity against Mycobacterium tuberculosis. Canadian J. Microbiol. 64(7), 483–491 (2018).
  Medline CASGoogle Scholar
• 49. Joshi H, Seniya S, Suryanarayanan V, Patidar N, Singh S, Jain V. Dissecting the structure-function relationship in lysozyme domain of mycobacteriophage D29-encoded peptidoglycan hydrolase. FEBS Letters. 591(20), 3276–3287 (2017).
  Medline CASGoogle Scholar
• 50. Pohane A, Joshi H, Jain V. Molecular dissection of phage endolysin. J. Biol. Chem. 289(17), 12085–12095 (2014).
  Medline CASGoogle Scholar
• 51. Kamilla S, Jain V. Mycobacteriophage D29 holin C-terminal region functionally assists in holin aggregation and bacterial cell death. FEBS J. 283(1), 173–190 (2015).
  MedlineGoogle Scholar
• 52. Pani B, Banerjee S, Chalissery J et al. Mechanism of inhibition of Rho-dependent transcription termination by bacteriophage P4 protein Psu. J. Biol. Chem. 284(37), 25459 (2009).
  Google Scholar
• 53. Sheppard C, Cámara B, Shadrin A et al. Inhibition of Escherichia coli RNAp by T7 Gp2 protein: role of negatively charged strip of amino acid residues in Gp2. J. Mol. Biol. 407(5), 623–632 (2011).
  Medline CASGoogle Scholar
• 54. Mekler V, Minakhin L, Sheppard C, Wigneshweraraj S, Severinov K. Molecular mechanism of transcription inhibition by phage T7 gp2 protein. J. Mol. Biol. 413(5), 1016–1027 (2011).
  Medline CASGoogle Scholar
• 55. Shadrin A, Sheppard C, Severinov K, Matthews S, Wigneshweraraj S. Substitutions in the Escherichia coli RNA polymerase inhibitor T7 Gp2 that allow inhibition of transcription when the primary interaction interface between Gp2 and RNA polymerase becomes compromised. Microbiology 158(11), 2753–2764 (2012).
  Medline CASGoogle Scholar
• 56. Shadrin A, Sheppard C, Savalia D, Severinov K, Wigneshweraraj S. Overexpression of Escherichia coli udk mimics the absence of T7 Gp2 function and thereby abrogates successful infection by T7 phage. Microbiology 159(Pt_2), 269–274 (2013).
  Medline CASGoogle Scholar
• 57. Lai M, Liu C, Jiang S et al. Antimycobacterial activities of endolysins derived from a mycobacteriophage, BTCU-1. Molecules 20(10), 19277–19290 (2015).
  Medline CASGoogle Scholar
• 58. Catalão M, Milho C, Gil F, Moniz-Pereira J, Pimentel M. A second endolysin gene is fully embedded in-frame with the lysA gene of Mycobacteriophage Ms6. PLoS ONE 6(6), e20515 (2011).
  Medline CASGoogle Scholar
• 59. Catalão M, Gil F, Moniz-Pereira J, Pimentel M. Functional analysis of the Holin-like proteins of Mycobacteriophage Ms6. J. Bacteriol. 193(11), 2793–2803 (2011).
  Medline CASGoogle Scholar
• 60. Gil F, Grzegorzewicz A, Catalão M, Vital J, McNeil M, Pimentel M. Mycobacteriophage Ms6 LysB specifically targets the outer membrane of Mycobacterium smegmatis. Microbiology 156(5), 1497–1504 (2010).
  Medline CASGoogle Scholar
• 61. Gil F, Catalão M, Moniz-Pereira J, Leandro P, McNeil M, Pimentel M. The lytic cassette of mycobacteriophage Ms6 encodes an enzyme with lipolytic activity. Microbiology 154(5), 1364–1371 (2008).
  Medline CASGoogle Scholar
• 62. Gan Y, Wu T, Liu P, Guo S. Characterization and classification of Bo4 as a cluster G mycobacteriophage that can infect and lyse M. tuberculosis. Archives of Microbiology 196(3), 209–218 (2014).
  Medline CASGoogle Scholar
• 63. Li Q, Zhou M, Fan X, Yan J, Li W, Xie J. Mycobacteriophage SWU1 gp39 can potentiate multiple antibiotics against Mycobacterium via altering the cell wall permeability. Scientific Reports 6(1), 28701 (2016).
  Medline CASGoogle Scholar
• 64. Fan X, Teng T, Wang H, Xie J. Biology of a novel Mycobacteriophage, SWU1, isolated from Chinese soil as revealed by genomic characteristics. J. Virology. 86(18), 10230–10231 (2012).
  Medline CASGoogle Scholar
• 65. Schooley R, Biswas B, Gill J et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii Infection. Antimicrob. Agents Chemother. 61(10), e00954–17 (2017).
  Medline CASGoogle Scholar
• 66. LaVergne S, Hamilton T, Biswas B, Kumaraswamy M, Schooley R, Wooten D. Phage therapy for a multidrug-resistant acinetobacter baumannii craniectomy site Infection. Open Forum Infect.Dis. 5(4), ofy064 (2018).
  MedlineGoogle Scholar
• 67. Wu N, Dai J, Guo M et al. Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients. Emerg. Microbes & Infect. 10(1), 612–618 (2021).
  Medline CASGoogle Scholar
• 68. Rabin N, Zheng Y, Opoku-Temeng C, Du Y, Bonsu E, Sintim H. Agents that inhibit bacterial biofilm formation. Future Med. Chem. 7(5), 647–671 (2015). • Comprehensive review article on antibiofilm agents and different strategy employed to inhibit or disperse biofilms and make them susceptible to antimicrobial agents. A summarized details about the in vivo antibiofilm activity of different peptides, sulfide, phenols, indole, imidazole, triazole, bromopyrrole and furanone etc.
  CASGoogle Scholar
• 69. Rogers S, Huigens R, Cavanagh J, Melander C. Synergistic effects between conventional antibiotics and 2-aminoimidazole-derived antibiofilm agents. Antimicrob. Agents Chemother. 54(5), 2112–2118 (2010).
  Medline CASGoogle Scholar
• 70. Reyes S, Huigens R III, Su Z, Simon M, Melander C. Synthesis and biological activity of 2-aminoimidazole triazoles accessed by Suzuki–Miyaura cross-coupling. Org. Biomol. Chem. 9(8), 3041 (2011).
  Medline CASGoogle Scholar
• 71. Richards J, Ballard T, Melander C. Inhibition and dispersion of Pseudomonas aeruginosa biofilms with reverse amide 2-aminoimidazole oroidin analogues. Org. Biomol. Chem. 6(8), 1356 (2008).
  Medline CASGoogle Scholar
• 72. Hu M, Zhang C, Mu Y, Shen Q, Feng Y. Indole affects biofilm formation in bacteria. Indian J. Microbiol. 50(4), 362–368 (2010).
  Medline CASGoogle Scholar
• 73. Di Martino P, Fursy R, Bret L, Sundararaju B, Phillips R. Indole can act as an extracellular signal to regulate biofilm formation of Escherichiacoliand other indole-producing bacteria. Canadian J. Microbiol. 49(7), 443–449 (2003).
  MedlineGoogle Scholar
• 74. Lee J, Lee J. Indole as an intercellular signal in microbial communities. FEMS Microbiol Rev. 34(4), 426–444 (2010).
  Medline CASGoogle Scholar
• 75. Ding X, Yin B, Qian L et al. Screening for novel quorum-sensing inhibitors to interfere with the formation of Pseudomonas aeruginosa biofilm. J. Med. Microbiol. 60(12), 1827–1834 (2011).
  Medline CASGoogle Scholar
• 76. Chauhan A, Jang M, Kim Y. Phloretin protects macrophages from E. coli-induced inflammation through the TLR4 signaling pathway. J. Microbiol. Biotechnol. 30(3), 333–340 (2020).
  Medline CASGoogle Scholar
• 77. Kim H, Park H. Ginger extract inhibits biofilm formation by Pseudomonas aeruginosa PA14. PLOS ONE. 8(9), e76106 (2013).
  Medline CASGoogle Scholar
• 78. Schiavone B, Rosato A, Marilena M et al. Biological evaluation of hyperforin and its hydrogenated analogue on bacterial growth and biofilm production. J. Nat. Products 76(9), 1819–1823 (2013).
  Medline CASGoogle Scholar
• 79. Murata R, Branco-de-Almeida L, Franco E et al. Inhibition of Streptococcus mutans biofilm accumulation and development of dental caries in vivo by 7-epiclusianone and fluoride. Biofouling 26(7), 865–872 (2010).
  Medline CASGoogle Scholar
• 80. Vikram A, Jesudhasan P, Jayaprakasha G, Pillai S, Patil B. Citrus limonoids interfere with Vibrio harveyi cell–cell signalling and biofilm formation by modulating the response regulator LuxO. Microbiology 157(1), 99–110 (2011).
  Medline CASGoogle Scholar
• 81. Vikram A, Jesudhasan P, Pillai S, Patil B. Isolimonic acid interferes with Escherichia coli O157:H7 biofilm and TTSS in QseBC and QseA dependent fashion. BMC Microbiol. 12(1), 261 (2012).
  Medline CASGoogle Scholar
• 82. Artini M, Papa R, Barbato G et al. Bacterial biofilm formation inhibitory activity revealed for plant derived natural compounds. Bioorg. Med. Chem. 20(2), 920–926 (2012).
  Medline CASGoogle Scholar
• 83. Flamini G, Catalano S, Caponi C, Panizzi L, Morelli I. Three anthrones from Rubus ulmifolius. Phytochemistry 59(8), 873–876 (2002).
  Medline CASGoogle Scholar
• 84. Panizzi L, Caponi C, Catalano S, Cioni P, Morelli I. In vitro antimicrobial activity of extracts and isolated constituents of Rubus ulmifolius. J. Ethnopharmacol. 79(2), 165–168 (2002).
  Medline CASGoogle Scholar
• 85. Quave C, Estévez-Carmona M, Compadre C et al. Ellagic acid derivatives from Rubus ulmifolius inhibit Staphylococcus aureus biofilm formation and improve response to antibiotics. PLOS ONE. 7(1), e28737 (2012).
  Medline CASGoogle Scholar
• 86. Payne D, Martin N, Parzych K, Rickard A, Underwood A, Boles B. Tannic acid inhibits Staphylococcus aureus surface colonization in an IsaA-dependent manner. Infection and Immunity 81(2), 496–504 (2013).
  Medline CASGoogle Scholar
• 87. Lee J, Kim Y, Ryu S, Cho M, Lee J. Ginkgolic acids and Ginkgo biloba extract inhibit Escherichia coli O157:H7 and Staphylococcus aureus biofilm formation. International J. Food Microbiol. 174, 47–55 (2014).
  Medline CASGoogle Scholar
• 88. Xiang-yang W, Liu-qing Y, Jun C, Xin-hua Y, Guo-hua X. Preparation of ginkgolic acid monomers and their antifungalactivity. Chemistry and Industry of Forest Products 23(04), (2003).
  Google Scholar
• 89. He J, Wang S, Wu T, Cao Y, Xu X, Zhou X. Effects of ginkgoneolic acid on the growth, acidogenicity, adherence, and biofilm of Streptococcus mutans in vitro. Folia Microbiologica 58(2), 147–153 (2012).
  MedlineGoogle Scholar
• 90. Inamuco J, Veenendaal A, Burt S et al. Sub-lethal levels of carvacrol reduce Salmonella Typhimurium motility and invasion of porcine epithelial cells. Veterinary Microbiology 157(1–2), 200–207 (2012).
  Medline CASGoogle Scholar
• 91. Nostro A, Roccaro A, Bisignano G et al. Effects of oregano, carvacrol and thymol on Staphylococcus aureus and Staphylococcus epidermidis biofilms. J. Med. Microbiol. 56(4), 519–523 (2007).
  Medline CASGoogle Scholar
• 92. Soni K, Oladunjoye A, Nannapaneni R et al. Inhibition and inactivation of Salmonella Typhimurium biofilms from polystyrene and stainless steel surfaces by essential oils and phenolic constituent carvacrol†. J. Food Protection 76(2), 205–212 (2013).
  Medline CASGoogle Scholar
• 93. Nostro A, Marino A, Blanco A et al. In vitro activity of carvacrol against staphylococcal preformed biofilm by liquid and vapour contact. J. Med. Microbiol. 58(6), 791–797 (2009).
  Medline CASGoogle Scholar
• 94. Burt S, Ojo-Fakunle V, Woertman J, Veldhuizen E. The natural antimicrobial carvacrol inhibits quorum sensing in Chromobacteriumviolaceum and reduces bacterial biofilm formation at sub-lethal concentrations. PLOS ONE. 9(4), e93414 (2014).
  MedlineGoogle Scholar
• 95. Benamar M, Melhaoui A, Zyad A, Bouabdallah I, Aziz M. Anti-cancer effect of two alkaloids: 2Rand 2S-bgugaine on mastocytoma P815 and carcinoma Hep. Nat. Product Res. 23(7), 659–664 (2009).
  Medline CASGoogle Scholar
• 96. Majik M, Naik D, Bhat C, Tilve S, Tilvi S, D'Souza L. Synthesis of (R)-norbgugaine and its potential as quorum sensing inhibitor against Pseudomonas aeruginosa. Bioorg. Med. Chem. Lett. 23(8), 2353–2356 (2013).
  Medline CASGoogle Scholar
• 97. Carneiro V, Santos H, Arruda F et al. Casbane diterpene as a promising natural antimicrobial agent against biofilm-associated infections. Molecules 16(1), 190–201 (2010).
  MedlineGoogle Scholar
• 98. Lee J, Cho H, Joo S et al. Diverse plant extracts andtrans-resveratrol inhibit biofilm formation and swarming of Escherichia coliO157:H7. Biofouling 29(10), 1189–1203 (2013).
  Medline CASGoogle Scholar
• 99. Piver B, Berthou F, Dreano Y, Lucas D. Differential inhibition of human cytochrome P450 enzymes by ε-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci. 73(9), 1199–1213 (2003).
  Medline CASGoogle Scholar
• 100. Cho H, Lee J, Ryu S, Joo S, Cho M, Lee J. Inhibition of Pseudomonas aeruginosa and Escherichia coli O157:H7 biofilm formation by plant metabolite ε-Viniferin. J. Agricultural and Food Chem. 61(29), 7120–7126 (2013).
  Medline CASGoogle Scholar
• 101. Bjarnsholt T, Jensen P, Rasmussen T et al. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology 151(12), 3873–3880 (2005).
  Medline CASGoogle Scholar
• 102. Persson T, Hansen T, Rasmussen T, Skindersø M, Givskov M, Nielsen J. Rational design and synthesis of new quorum-sensing inhibitors derived from acylated homoserine lactones and natural products from garlic. Org. Biomol. Chem. 3(2), 253–262 (2005).
  Medline CASGoogle Scholar
• 103. Jakobsen T, van Gennip M, Phipps R et al. Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing. Antimicrob. Agents Chemother. 56(5), 2314–2325 (2012).
  Medline CASGoogle Scholar
• 104. Cady N, McKean K, Behnke J et al. Inhibition of biofilm formation, quorum sensing and infection in Pseudomonas aeruginosa by natural products-inspired organosulfur compounds. PLOS ONE 7(6), e38492 (2012).
  Medline CASGoogle Scholar
• 105. Olaru I, von Groote-Bidlingmaier F, Heyckendorf J, Yew W, Lange C, Chang K. Novel drugs against tuberculosis: a clinician's perspective. Eur. Respir. J. 45(4), 1119–1131 (2014).
  MedlineGoogle Scholar
• 106. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO Document Production Services, Geneva, Switzerland, 93 (2014).
  Google Scholar
• 107. Loddenkemper R, Sagebiel D, Brendel A. Strategies against multidrug-resistant tuberculosis. Eur. Respir. J. 20(Suppl. 36), 66S–77s (2002).
  MedlineGoogle Scholar
• 108. Sharma S, Mohan A. Multidrug-resistant tuberculosis. Indian J. Med. Res. (2004). https://pubmed.ncbi.nlm.nih.gov/15520486/
  Google Scholar
• 109. Cui X, Lü Y, Yue C. Development and research progress of anti-drug resistant bacteria drugs. Infect. Drug Resist. 14, 5575–5593 (2021).
  Medline CASGoogle Scholar
• 110. Babb R, Pirofski L. Help is on the way: monoclonal antibody therapy for multi-drug resistant bacteria. Virulence 8(7), 1055–1058 (2017).
  MedlineGoogle Scholar
• 111. Motley M, Banerjee K, Fries B. Monoclonal antibody-based therapies for bacterial infections. Curr. Opin. Infect. Dis. 32(3), 210–216 (2019). •• An excellent review article on use of monoclonal antibodies against bacterial infections. It includes comprehensive details of different monoclonal at preclinical developmental stage as well as details about various monoclonal antibodies that are in clinical trial stage for bacterial diseases.
  Medline CASGoogle Scholar
• 112. Zrelovs N, Kurbatska V, Rudevica Z, Leonchiks A, Fridmanis D. Sorting out the superbugs: potential of SortaseA inhibitors among other antimicrobial strategies to tackle the problem of antibiotic resistance. Antibiotics 10(2), 164 (2021).
  CASGoogle Scholar
• 113. Wang C, Hsieh Y, Powers Z, Kao C. Defeating antibiotic-resistant bacteria: exploring alternative therapies for a post-antibiotic era. Int. J. Mol. Sci. 21(3), 1061 (2020). • Comprehensive review article on recent developments made in the field of alternative therapy to tackle antimicrobial resistance. It includes various innovative approaches to tackle antimicrobial resistance (AMR) problems of post-antibiotic era, such a santi-signal transduction agents, combinational therapy, bioengineered bacteriophages, microbiome alterations, anti-virulence, and anti-toxin to fight against antibiotic-resistant pathogens.
  CASGoogle Scholar
• 114. Liu S, Moayeri M, Leppla S. Anthrax lethal and edema toxins in anthrax pathogenesis. Trends in Microbiol. 22(6), 317–325 (2014).
  MedlineGoogle Scholar
• 115. Moayeri M, Leppla S, Vrentas C, Pomerantsev A, Liu S. Anthrax pathogenesis. Ann. Rev. Microbiol. 69(1), 185–208 (2015).
  Medline CASGoogle Scholar
• 116. Kummerfeldt C. Raxibacumab: potential role in the treatment of inhalational anthrax. Infect.Drug Resist. 7, 101–9 (2014).
  MedlineGoogle Scholar
• 117. Xu W, Ohanjandian L, Sun J et al. A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: a need for more robust study designs and results. PLOS ONE 12(8), e0182879 (2017).
  MedlineGoogle Scholar
• 118. Patil K, Bagade S, Bonde S, Sharma S, Saraogi G. Recent therapeutic approaches for the management of tuberculosis: challenges and opportunities. Biomed. Pharmacother. 99, 735–745 (2018).
  Medline CASGoogle Scholar
• 119. Lay C, Dridi L, Bergeron M, Ouellette M, Fliss I. Nisin is an effective inhibitor of Clostridium difficile vegetative cells and spore germination. J. Med. Microbiol. 65(2), 169–175 (2016).
  MedlineGoogle Scholar
• 120. Haddad Kashani H, Schmelcher M, Sabzalipoor H, Seyed Hosseini E, Moniri R. Recombinant endolysins as potential therapeutics against antibiotic-resistant Staphylococcus aureus: current status of research and novel delivery strategies. Clin Microbiol Rev. 31(1), e00071–17 (2018).
  MedlineGoogle Scholar
• 121. Antimicrobial resistance [Internet]. Who.int. (2022). www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
  Google Scholar
• 122. Lei J, Sun L, Huang S et al. The antimicrobial peptides and their potential clinical applications. Am. J. Transl. Res. 11(7), 1 (2019).
  MedlineGoogle Scholar
• 123. Sarkar T, Chetia M, Chatterjee S. Antimicrobial peptides and proteins: from nature's reservoir to the laboratory and beyond. Front Chem. 9, 691532 (2021).
  Medline CASGoogle Scholar
• 124. Loc-Carrillo C, Abedon S. Pros and cons of phage therapy. Bacteriophage 1(2), 111–114 (2011).
  MedlineGoogle Scholar
• 125. Srinivasan R, Santhakumari S, Poonguzhali P, Geetha M, Dyavaiah M, Xiangmin L. Bacterial biofilm inhibition: afocused review on recent therapeutic strategies for combating the biofilm mediated infections. Front. Microbiol. 12, 676458 (2021).
  MedlineGoogle Scholar
• 126. Roy R, Tiwari M, Donelli G, Tiwari V. Strategies for combating bacterial biofilms: a focus on anti-biofilm agents and their mechanisms of action. Virulence 9(1), 522–554 (2018).
  Medline CASGoogle Scholar
• 127. Murphy A, Zheng L. Small molecule drugs with immunomodulatory effects in cancer. Hum. Vaccines Immunother. 11(10), 2463–2468 (2015).
  MedlineGoogle Scholar
• 128. Bascones-Martinez A, Mattila R, Gomez-Font R, Meurman J. Immunomodulatory drugs: oral and systemic adverse effects. Medicina Oral Patología Oral y Cirugia Bucal. e24–e31 (2014).
  MedlineGoogle Scholar
• 129. Casadevall A, Dadachova E, Pirofski L. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2(9), 695–703 (2004).
  Medline CASGoogle Scholar
• 130. Zrelovs N, Kurbatska V, Rudevica Z, Leonchiks A, Fridmanis D. Sorting out the superbugs: potential of sortase A inhibitors among other antimicrobial strategies to tackle the problem of antibiotic resistance. Antibiotics 10(2), 164 (2021). • This article gives insight into various alternative approaches and recent advance made to tackle AMR problems. It gives rational behind the use of Sortase A inhibitors as anti-virulence agent against bacterial pathogens advocates its use as alternative approach to tackle drug resistance pathogens.
  CASGoogle Scholar
• 131. Cascioferro S, Raffa D, Maggio B, Raimondi M, Schillaci D, Daidone G. Sortase A inhibitors: recent advances and future perspectives. J. Med. Chem. 58(23), 9108–9123 (2015).
  Medline CASGoogle Scholar
• 132. Grover A. Use of allosteric targets in the discovery of safer drugs. Med. Princ. Pract. 22(5), 418–426 (2013).
  MedlineGoogle Scholar
• 133. Abdel-Magid A. Allosteric modulators: an emerging concept in drug discovery. ACS Med. Chem. Lett. 6(2), 104–107 (2015).
  MedlineGoogle Scholar